Freenome, Inc.
corporate_fare Company Profile
Freenome, Inc. (NASDAQ:FRNM) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 4 items for FRNM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-18, rated 9/10. Across its 4 most recent items scored 7 or higher, the top rating is 9/10, with 3 rated 8 or above. Recent SEC coverage for FRNM spans S-1, 8-K/A.
Recent high-impact activity:
- Freenome Registers 75.1M Shares for Resale by Existing Holders, Creating Significant Stock Overhang
- Freenome Files Amended 8-K with First Post-Merger Financials and Pro Forma Data
- FDA Grants Breakthrough Status to Freenome's Lung Cancer Blood Test
- FDA Approves Freenome's SimpleScreen CRC Blood Test; Abbott to Commercialize
Financial Snapshot
Short Interest & Short Volume
2.14 days to coverFINRA reported short interest of 1,696,752 shares in FRNM as of the September 15, 2026 settlement, a 10.8% increase from the prior period — about 2.1 days to cover at its recent average daily volume. On October 2, 2026, 87.4% of FRNM volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for FRNM, detected from its recent SEC filings · based on capital-structure filings through 2026-08-27.
Resale Registration Effective · No Company Proceeds
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →